Roivant Sciences Publishes Presentation on Brepocitinib Phase 3 Results in Non-Infectious Uveitis

• Roivant Sciences published “Brepocitinib in NIU: CLARITY Topline Results,” reporting positive Phase 3 results in non-infectious uveitis.
• Brepocitinib met the primary endpoint and all secondary endpoints in both CLARITY trials.
• Median time to treatment failure exceeded 48 weeks versus approximately 12 weeks for placebo, with p<0.0001 in both trials.
• Steroid-free quiescence reached 62% at one year, a placebo-adjusted improvement of 41 percentage points.
• A supplemental new drug application filing for non-infectious uveitis is planned for the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.